Document is current
Any future updates will be listed below
-
Authors
Shahkhali, Morvarid Ghamgosar
Liu, Lang
Somerville, Emma N.
Noyce, Alastair J.
Gan-Or, Ziv
Senkevich, Konstantin
-
Funding
Funding for this research was provided by:
The Canadian Consortium on Neurodegeneration in Aging
The GBA1-Canada initiative
The Hilary and Galen Weston Foundation and The Van Berkom family
- License Information
-
More Information
Article History
Received: 6 September 2025
Accepted: 28 October 2025
First Online: 9 December 2025
Competing interests
: Z.G-O. received consultancy fees from Lysosomal Therapeutics Inc. (LTI), Idorsia, Prevail Therapeutics, Ono Therapeutics, Denali, Handl Therapeutics, Neuron23, Bial Biotech, Bial, UCB, Capsida, Vanqua bio, Congruence Therapeutics, Takeda, Jazz Guidepoint, Lighthouse and Deerfield. Z.G-O. is affiliated with npj Parkinson’s Disease as Associate Editor. A.J.N. reports grants from Parkinson’s UK, Barts Charity, Cure Parkinson’s, National Institute for Health and Care Research, Innovate UK, the Medical College of Saint Bartholomew’s Hospital Trust, Alchemab, Aligning Science Across Parkinson’s Global Parkinson’s Genetics Program (ASAP-GP2) and the Michael J Fox Foundation. A.J.N. reports fees from AstraZeneca, AbbVie, Bial, and Britannia. K.S. reports grant from Parkinson Canada, Aligning Science Across Parkinson’s Global Parkinson’s Genetics Program (ASAP-GP2) and is a consultant for Acurex. The remaining authors declare no competing interests.
